<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437356</url>
  </required_header>
  <id_info>
    <org_study_id>8049201834825</org_study_id>
    <nct_id>NCT03437356</nct_id>
  </id_info>
  <brief_title>Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drugs in Persistent Atrial Fibrillation</brief_title>
  <acronym>POWDER-AF2</acronym>
  <official_title>Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Persistent Atrial Fibrillation: a Prospective Multi-centre Randomized Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the POWDER 1 study, paroxysmal atrial fibrillation (AF) patients undergoing conventional
      contact force (CF)-guided PVI were investigated. Patients were randomized between continuing
      previously ineffective antiarrhythmic drug therapy (ADT) or stopping ADT at the end of the
      blanking period. This trial, showed an added value of ADT after ablation (in support of
      'hybrid rhythm control' as an alternative treatment strategy for AF in some patients).

      In the POWDER 2 trial, an analogue study in persistent AF patients will be performed. All
      patients will undergo ablation index (AI)- and IL distance (ILD)-guided PVI (just like in
      VISTAX trial) and continue previously ineffective ADT during the blanking period. 'PVI only'
      was chosen as the ablation strategy according to the STAR AF trial findings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: In real-life, ADT is often continued after catheter ablation for persistent AF.
      No study investigated whether ADT continued beyond the blanking period reduces recurrence
      after a first ablation for persistent AF.

      Purpose: The aim of this trial is to investigate whether continued ADT (ADT ON) reduces
      recurrence of atrial tachyarrhythmia (ATA) in the first year after contact-force guided PVI
      for persistent AF.

      Hypothesis: Continued use of ADT beyond the blanking period reduces recurrence of ATA in the
      first year after PVI .

      Eligibility: Subjects that are planned for catheter ablation for persistent AF.

      Inclusion: Symptomatic persistent AF resistant to ongoing or prior ADT (failed ADT).
      Persistent AF is defined as the presence of any prior AF episode ≥7 days.

      Exclusion: Any prior AF episode ≥12 months, any recurrence of AF &lt;3 days after cardioversion.

      Echo criteria: advanced valvular heart disease, left atrium (LA) volume &gt;37ml/m2, left
      ventricle (LV) ejection fraction &lt;35% (except if suspected tachycardiomyopathy), septal
      diameter &gt;15mm, Life expectancy &lt;1 year, BMI &gt;35.

      Trial design: This is a prospective, multi-center, randomized (1:1), open label, blinded
      endpoint study (PROBE). Eligible subjects who sign the study informed consent form at the
      time of procedural planning will be randomized into one of two study arms: In the ADT off arm
      (ADT OFF), ADT will be stopped at 3 months after the first procedure. In the ADT ON arm, ADT
      will be continued at 3 months until 1 year follow up (FU).

      First ablation and blanking: In both arms, catheter ablation will consist of 'CLOSE'-guided
      PVI only (abl index and interlesion distance). High-density voltage mapping will be performed
      during sinus rhythm. After ablation, ADT is continued/restarted during the 3-month blanking
      period (except for amiodarone). During the blanking period cardioversions are allowed. At the
      3-month visit, all patients will be cardioverted if ATA is present.

      Repeat ablation strategy: In case of recurrence of ATA's after 3 months, a repeat ablation is
      recommended. Depending on the reconnection status of the pulmonary veins (PV), repeat
      ablation will consist of either PVI only or a patient-tailored ablation approach (antral
      isolation, superior vena cava (SVC) isolation, isolation of low voltage, linear lesions).
      Patients stay on the ADT ON or ADT OFF arm.

      Primary Endpoint: Any documented ATA (atrial fibrillation, AF, atrial tachycardia, AT, atrial
      flutter, AFL) lasting &gt;30s from 3 months through 12 month follow-up after the first
      procedure.

      Secondary Endpoints:

      ATA recurrence in patients with early peristent AF (defined as AF ≤3 months) Incidence of
      repeat ablation Unscheduled visits and hospitalisation ADT or ablation related adverse events
      QOL and symptoms Outcome after repeat ablation

      Sample size: In the ADT OFF group ATA recurrence after a first PVI is expected to be 50%. ADT
      are expected to reduce ATA recurrence to 30%. Given power of 80% and α of 0.05 up to 200
      subjects need be enrolled in this study (20 per center)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any documented AF/atrial tachycardia (AT)/atrial flutter (AFL) recurrence</measure>
    <time_frame>From 3 to 12 months after PVI</time_frame>
    <description>Recurrence will be considered as AF/AT/AF lasting &gt;30 seconds, as measured by 1-day Holter monitoring at 6 month after PVI, 7-day Holter (screening for AF between 48 hours and 7 days) at 12 months after PVI, and by any standard of care or unscheduled arrhythmia monitoring documentation throughout the follow-up (ie. from 3 to 12 months after PVI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AF/atrial tachycardia (AT)/atrial flutter (AFL) recurrence in early persistent AF</measure>
    <time_frame>From 3 to 12 months after PVI</time_frame>
    <description>Incidence of recurrence of early persistent AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat ablation</measure>
    <time_frame>From 3 to 12 months after PVI</time_frame>
    <description>Incidence of repeat ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unscheduled health care visits and hospitalizations</measure>
    <time_frame>From 3 to 12 months after PVI</time_frame>
    <description>Incidence of unscheduled health care visits and/or hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADT-related adverse events</measure>
    <time_frame>From 3 to 12 months after PVI</time_frame>
    <description>Adverse events related to continuation of ADT in the ON group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ablation-related adverse events</measure>
    <time_frame>From 0 to 12 months after ablation</time_frame>
    <description>Adverse events related to ablation in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment (SF-36)</measure>
    <time_frame>At Enrollment, and at 3 months, 6 months, and 12 months after ablation</time_frame>
    <description>At each scheduled visit, the patients will fill the SF-36 questionnaire for the assessment of Quality of life before and after ablation in both groups. SF-36 individual scores (0-100) will be converted into z-scores as standardized combined scores (mean 50, standard deviation 10) for US population (Ware et al.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF symptom scores</measure>
    <time_frame>At Enrollment, and at 3 months, 6 months, and 12 months after ablation</time_frame>
    <description>At each scheduled visit, the patients will fill AF checklist: 16 questions of AF severity (score = minimum 16, maximum 48) and 16 questions of AF frequency (score = minimum 16, maximum 64) for qualitative assessment of AF symptoms before and after ablation in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of recurrence</measure>
    <time_frame>At baseline</time_frame>
    <description>Any conventional clinical characteristics acquired at baseline that could predict recurrence of AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome after repeat ablation</measure>
    <time_frame>From 3 to 12 months after first PVI</time_frame>
    <description>Incidence of AF recurrence after multiple ablation procedures (if applicable)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>ADT ON Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>'CLOSE'-guided PVI with continuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT OFF Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>'CLOSE' guided PVI with discontinuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulmonary vein isolation using CLOSE protocol</intervention_name>
    <description>'CLOSE' protocol: Ablation index &gt; 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index &gt; 550 at the anterior wall, and inter-lesion distance &lt; 6.0mm</description>
    <arm_group_label>ADT ON Group</arm_group_label>
    <arm_group_label>ADT OFF Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrhythmic drug therapy (ADT)</intervention_name>
    <description>During the first 3 months after PVI, patients continue oral anticoagulants and antiarrhythmic drug therapy (ADT). ADT is a continuation (or restart) of previously ineffective Class IC and III ADT. At the time of discharge, dosage is optimized according to the 2016 ESC guidelines on AF management.
Preferred dosages:
Flecainide: Tambocor or Flecainide EG 100mg b.i.d., Apocard R 100 to 200mg overdose (OD) Propafenone: Rytmonorm or Propafenone EG 300 mg b.i.d., except 225 mg b.i.d. if ≥70 years or &lt;70 kg Sotalol: Sotalex or Sotalol EG 80mg b.i.d., Except 80mg t.i.d. if men &lt; 70 years, Cr &lt;1.5mg/dl, &gt;70kg, except 80 mg OD if female &gt;70 years or Cr &gt;1.2mg/dl
In case of amiodarone intake before PVI, amiodarone is switched to sotalol or class IC ADT.</description>
    <arm_group_label>ADT ON Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with symptomatic persistent AF, resistant to ongoing or prior ADT (failed ADT)
             Patients is considered to have persistent AF if the patient has suffered any prior AF
             episode ≥7 days (ESC 2016 guidelines).

          2. Before PVI, there was at least one episode of persistent AF in the last year.

          3. Signed Patient Informed Consent Form.

          4. Age 18 years or older.

          5. Able and willing to comply with all follow-up testing and requirements.

        Exclusion Criteria:

          1. Patients not willing or not suited to take any class IC or III ADT.

          2. Any prior AF episode ≥12 months, or any recurrence of AF &lt;3 days after cardioversion.

          3. Presence of structural heart disease on echo criteria:

             severe valvular heart disease LA volume &gt;37ml/m2 and/or LA size &gt;50mm LV ejection
             fraction &lt;35% (except if suspected tachycardiomyopathy) septal diameter &gt;15mm

          4. BMI &gt;35

          5. Recent (&lt;3 months) coronary artery bypass grafting (CABG), myocardial infarction,
             cerebral vascular accident (CVA), uncontrolled heart failure or angina

          6. Active illness or systemic infection or sepsis

          7. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac
             cause

          8. Awaiting cardiac transplantation or other cardiac surgery

          9. Documented left atrial thrombus or atrial myxoma on imaging

         10. History of blood clotting or bleeding abnormalities

         11. Enrollment in any other study evaluating another device or drug

         12. Women with childbearing potential

         13. Life expectancy less than 12 months

         14. Contraindication for catheter ablation (intramural thrombus, tumor or other
             abnormality that precludes catheter introduction, contraindication to anticoagulation
             therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mattias Duytschaever, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint-Jan Hospital Bruges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mattias Duytschaever, MD, PhD</last_name>
    <phone>003250452652</phone>
    <email>Mattias.Duytschaever@azsintjan.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly De Jaegher</last_name>
    <phone>0032 50 45 28 96</phone>
    <email>Kelly.DeJaegher@azsintjan.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernadette Mastnak</last_name>
      <email>bernadette.mastnak@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Graz Scherr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy De Knijf</last_name>
      <email>Kathy.De.Knijf@olvz-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Tom De Potter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Hospital</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly DeJaegher</last_name>
      <email>Kelly.DeJaegher@azsintjan.be</email>
    </contact>
    <contact_backup>
      <last_name>Katrien Derycker</last_name>
      <email>Katrien.Derycker@azsintjan.be</email>
    </contact_backup>
    <investigator>
      <last_name>Mattias Duytschaever, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastien knecht, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tavernier Rene, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evi Theunissen</last_name>
      <email>Evi.Theunissen@zol.be</email>
    </contact>
    <investigator>
      <last_name>Maximo Rivero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis Hasselt</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arne Janssen</last_name>
      <email>Arne.Janssen@jessazh.be</email>
    </contact>
    <investigator>
      <last_name>Johan Vijgen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Department of Clinical Medicine</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Signe Traynor</last_name>
      <email>signtray@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Peter Lukac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Gerdes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steen Kristiansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Laage-Petersen</last_name>
      <email>Julie.Laage-Petersen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Arne Johannessen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Véronique Midenet</last_name>
      <email>v.midenet@chru-nancy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christelle Simonot</last_name>
      <email>c.simonot@chru-nancy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christian De Chillou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cecile Naudin</last_name>
      <email>Cecile.naudin@clinique-a-pare.fr</email>
    </contact>
    <investigator>
      <last_name>Alexander Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp Hospital</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kars Neven, MD</last_name>
      <email>kars.neven@krupp-krankenhaus.de</email>
    </contact>
    <investigator>
      <last_name>Kars Neven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinic Casilino Division of Cardiology</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ermenegildo De Ruvo, MD</last_name>
      <email>bioetica.polcas@eurosanita.it</email>
    </contact>
    <investigator>
      <last_name>Ermenegildo De Ruvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital Department of Cardiology</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeroen Stevenhagen, MD</last_name>
      <email>Y.Stevenhagen@mst.nl</email>
    </contact>
    <investigator>
      <last_name>Jeroen Stevenhagen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Asier Molinero</last_name>
      <email>electrofisiologia.germanstrias@gencat.cat</email>
    </contact>
    <investigator>
      <last_name>Felipe Bisbal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitta Mehmann</last_name>
      <email>brigitta.mehmann@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Richard Kobza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Berte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Mattias Duytschaever</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>persistent atrial fibrillation</keyword>
  <keyword>pulmonary vein isolation</keyword>
  <keyword>antiarrhythmic drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

